1. The participant has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms), within 6 months prior to randomization.2.The participant has either of the following conditions:-HIV with a recent viral load >50 copies/mL (regardless of CD4 count) or an AIDS defining illness in the past 6 months.Note: Participants with HIV may only be enrolled if on a stable antiretroviral therapy regimen.3.The participant has a history of HBV or HCV infection with any of the following:Cirrhosis,End-stage liver disease,Hepatocellular carcinoma, AST and/or ALT >3X upper limit of normal at screening.4.The participant has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator. 5.The participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents.6.The participant has received, is taking, or is anticipated to require any prohibited therapies. 7. The participant has received a COVID-19 vaccine with the first dose 7 days or more prior to randomization.8.The participant is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.9.The participant is living in a household of more than 10 people. 10. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

1. The participant has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms), within 6 months prior to randomization.2.The participant has either of the following conditions:-HIV with a recent viral load >50 copies/mL (regardless of CD4 count) or an AIDS defining illness in the past 6 months.Note: Participants with HIV may only be enrolled if on a stable antiretroviral therapy regimen.3.The participant has a history of HBV or HCV infection with any of the following:Cirrhosis,End-stage liver disease,Hepatocellular carcinoma, AST and/or ALT >3X upper limit of normal at screening.4.The participant has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator. 5.The participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents.6.The participant has received, is taking, or is anticipated to require any prohibited therapies. 7. The participant has received a COVID-19 vaccine with the first dose 7 days or more prior to randomization.8.The participant is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.9.The participant is living in a household of more than 10 people. 10. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.